Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: HER2 Positive Breast Cancer
Interventions: DRUG: Pyrotinib and Trastuzumab plus Vinorelbine
Sponsor: Henan Cancer Hospital